CVS Health reported $2.9 billion in fourth quarter net income as the company begins to get a handle on costs that have hit ...

CVS CEO David Joyner offered support for Trump administration goals, took a swipe at hospitals and Big Pharma, and said his ...

CVS' Q4 2025 saw record revenue, but rising medical costs in Aetna drove a $1B cut to FY 2026 cash flow guidance, now at $9B.

The results signal steady progress in the health-care giant's aggressive turnaround plan under CEO David Joyner, who stepped into the role in late 2024.

The healthcare giant outperformed to close out 2025, and expects its finances to improve further this year. Still, proposed ...

The company maintained its 2026 earnings forecast, with guidance falling short of expectations despite stronger fourth-quarter results.

CVS Health’s rehabilitation efforts to return to full strength appear to be on track after a strong fourth quarter. The ...

CVS Health (CVS) stock dips even as the company posts a double beat with Q4 2025 results after its full-year outlook disppointed investors. Read more here.

CVS Health CEO David Joyner told investors on Tuesday that the recently proposed rates for the 2027 Medicare Advantage plan year don't fully account for the current environment.

CVS Health reported higher fourth-quarter and full-year revenues in 2025, driven by growth across its pharmacy, health ...

In the health-insurance business, sales rose 10.1% to $36.3 billion. The health-services segment, which includes its pharmacy-benefits manager, saw a 9.0% increase in revenue to $51.2 billion, while ...

CVS Health earnings came in ahead of analyst forecasts but the company is concerned about Medicare rates.